<?xml version="1.0" encoding="utf-8" ?>
<feed xmlns="http://www.w3.org/2005/Atom">
<title>Thelansis - Latest News</title>
<link href="https://news.prfree.org/rss/thelansis/latest.xml"></link>
<updated>2026-07-21T21:37:25+00:00</updated>
<id>urn:uuid:04955b3b-53cd-83f2-b8fd-aca8491b1967</id>
<entry>
<title>Chemotherapy Induced Peripheral Neuropathy (CIPN) - Market Outlook, Epidemiology, Forecast &amp; Competitive Landscape Report (2020– 2030)</title>
<link href="https://news.prfree.org/@thelansis/chemotherapy-induced-peripheral-neuropathy-cipn-market-outlook-epidemiology-forecast-competitive-landscape-report-2020-2030-6rmy4bd8jkb4"></link>
<id>urn:uuid:b57271e2-b4b2-09a3-2f5c-14bfab8844f8</id>
<summary type="html"><![CDATA[According to Thelansis the estimated total patient pool of chemotherapy induced peripheral neuropathy (CIPN) in 8 MM countries are reported to be 3.35 MN in 2020, 3.47 MN in 2025 and 3.57 MN by 2030.]]></summary>
<updated>2021-07-21T11:42:34+00:00</updated>
</entry>
<entry>
<title>Friedreich’s ataxia (FA) – Market Outlook and Competitive Landscape Report 2020– 2030” USA, Germany, France, Italy, Spain &amp; UK</title>
<link href="https://news.prfree.org/@thelansis/friedreich-s-ataxia-fa-market-outlook-and-competitive-landscape-report-2020-2030-usa-germany-france-italy-spain-uk-p7ke8qjebmwx"></link>
<id>urn:uuid:0f88f5d4-ee5c-a7c6-db97-0e2f1f07717f</id>
<summary type="html"><![CDATA[The Friedreich’s ataxia (FA) market insight report provides a comprehensive view of disease events, severity, identified and emerging biomarkers, treatment guidelines, epidemiology, market forecast, etc.]]></summary>
<updated>2021-06-30T06:47:32+00:00</updated>
</entry>
<entry>
<title>Charcot-Marie-Tooth (CMT) – Market Outlook, Forecast and Competitive Landscape report- 2019-2030</title>
<link href="https://news.prfree.org/@thelansis/charcot-marie-tooth-cmt-market-outlook-forecast-and-competitive-landscape-report-2019-2030-3rm6ry5ejmeq"></link>
<id>urn:uuid:5979e821-7fd2-0d17-dfd9-71a6e7a8b6df</id>
<summary type="html"><![CDATA[Charcot-Marie-Tooth disease (CMT) is one of a group of disorders that cause damage to the peripheral nerves.]]></summary>
<updated>2021-05-18T11:03:22+00:00</updated>
</entry>
<entry>
<title>Acromegaly – Market outlook, Epidemiology, Market Fore- cast and Competitive Landscape Report – 2020 To 2030</title>
<link href="https://news.prfree.org/@thelansis/acromegaly-market-outlook-epidemiology-market-fore-cast-and-competitive-landscape-report-2020-to-2030-3rmw8narxkn4"></link>
<id>urn:uuid:cbb72483-f31b-574c-a864-1c71c5a6f83e</id>
<summary type="html"><![CDATA[Thelansis “Acromegaly - Market outlook, Epidemiology, Market Forecast and Competitive Land- scape - 2020 To 2030 ”.]]></summary>
<updated>2021-05-12T10:28:46+00:00</updated>
</entry>
<entry>
<title>Thelansis Crohn’s Disease (CD) Market Outlook and Competitive Landscape Report 2015 - 2030</title>
<link href="https://news.prfree.org/@thelansis/thelansis-crohn-s-disease-cd-market-outlook-and-competitive-landscape-report-2015-2030-jekrrjdwpkxr"></link>
<id>urn:uuid:1964364c-50dd-8c78-334a-83e4cab27c74</id>
<summary type="html"><![CDATA[Thelansis Crohn’s disease (CD) is a chronic disorder characterized by exacerbations and periods of remission that cause inflammation of the gastrointestinal (GI) tract.]]></summary>
<updated>2021-03-27T07:31:01+00:00</updated>
</entry>
</feed>